The CEO of a company that marketed stem cell-based products allegedly linked to 19 hospitalizations was sentenced Sept. 30 to serve 36 months in prison after he pleaded guilty to a felony charge of introducing an unapproved new drug into interstate commerce with the intent to defraud (United States v. Kosolcharoen, No. 8:24-cr-00088-ODW (C.D. Cal.)). John W. Kosolcharoen had ... Read More